Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study) (Support Care Cancer, (2016), 10.1007/s00520-015-2861-z);Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

Supportive Care in Cancer

Volumn 24, Issue 2, 2016, Pages 911-925

  Gascón, Pere ^a   Aapro, Matti ^b   Ludwig, Heinz ^c   Bokemeyer, Carsten ^d   Boccadoro, Mario ^e   Turner, Matthew ^f   Denhaerynck, Kris ^g   MacDonald, Karen ^g   Abraham, Ivo ^g,h  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CLINIQUE DE GENOLIER   (Switzerland)

^c WILHELMINEN HOSPITAL   (Austria)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e Azienda Ospedaliero Universitaria San Giovanni Battista di Torino   (Italy)

^f Sandoz Pharma Ltd   (Switzerland)

^g Matrix45   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

Author keywords

Biosimilar; Chemotherapy induced neutropenia; Febrile neutropenia; Filgrastim; Granulocyte colony stimulating factor; Prophylaxis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; FILGRASTIM; LACTATE DEHYDROGENASE; URIC ACID; BIOSIMILAR AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ABSCESS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BACKACHE; BLEEDING; BONE PAIN; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL EFFECTIVENESS; CONFUSION; CONSCIOUSNESS DISORDER; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HOSPITALIZATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; SKIN BLEEDING; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; ADVERSE EFFECTS; AGED; CHEMICALLY INDUCED; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; FEVER; INDUCTION CHEMOTHERAPY; MIDDLE AGED; NEOPLASMS;

ADULT; AGED; BIOSIMILAR PHARMACEUTICALS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; FEMALE; FEVER; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84952870632     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2991-3     Document Type: Erratum

References (34)

1. Lalami Y, Paesmans M, Muanza F et al (2006) Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol 17:507–514
2. Lalami Y, Paesmans M, Aoun M et al (2004) A prospective randomized evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia. Support Care Cancer 12:725–730
3. Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427–437
4. Lyman GH, Dale DC, Culakova E et al (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24:2475–2484
5. Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90:190–199
6. Kuderer N, Dale D, Crawford J et al (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor or febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158–3167
7. Crawford J, Dale D, Lyman GH (2003) Chemotherapy-induced neutropenia. Cancer 100:228–237
8. Komorokji R, Lyman G (2004) The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Exp Opin Biol Ther 4:1897–1910
9. Aapro M, Cameron D, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapyinduced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433–2453
10. Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 47:8–32
11. Gridelli C, Aapro M, Barni S et al (2007) Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. Crit Rev Oncol Hematol 63:53–64
12. Raposo CG, Marin AP, Barón MG (2006) Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia. Clin Transl Oncol 8:729–734
13. Wingard JR, Elmongy M (2009) Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics. Crit Rev Oncol Hematol 72:144–154
14. Morrison V, Wong M, Hershman D et al (2007) Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 13:337–348
15. 15 National Comprehensive Center Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myeloid growth factors version 2.2014. Available at http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf. Accessed 2 Oct 2014
16. Klastersky J, Awada A (2011) Prevention of febrile neutropenia in chemotherapytreated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice? Crit Rev Oncol Hematol 78:17–23
17. Klastersky J, Awada A, Paesmans M, Aoun M (2011) Febrile neutropenia: a critical review of the initial management. Crit Rev Oncol Hematol 78:185–194
18. Weise M, Bielsky MC, De Smet K et al (2011) Biosimilars – why terminology matters. Nat Biotechnol 29:690–693
19. Gascón P, Fuhr U, Sörgel F et al (2010) Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol 21:1419–1429
20. Abraham I, Tharmarajah S, MacDonald K (2013) Clinical safety of biosimilar recombinant human granulocyte colony stimulating factors. Exp Opin Drug Saf 12:235–246
21. Tharmarajah S, Mohammed A, Bagalagel A et al (2014) Clinical efficacy and safety of Zarzio (EP2006), a biosimilar recombinant human granulocyte colony stimulating factor. Biogeosciences 4:1–9
22. Verpoort K, Möhler TM (2012) A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre. Ther Adv Med Oncol 4:289–293
23. Salesi N, Di Cocco B, Veltri E (2012) Biosimilar medicines in oncology: singlecenter experience with biosimilar G-CSF. Fut Oncol 8:625–630
24. Gascón P, Tesch H, Verpoort K et al (2013) Clinical experience with Zarzio® in Europe: what have we learned? Support Care Cancer 21:2925–2932
25. Bonig H, Becker PS, Schwebig A, Turner M (2015) Biosimilar granulocyte-colonystimulating factor for healthy donor stem cell mobilization: need we be afraid? Transfusion 55:430–439
26. Gascón P, Aapro M, Ludwig H et al (2011) Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Crit Rev Oncol Hematol 77:184–197
27. Gascón P, Aapro M, Ludwig H et al (2011) Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. Crit Rev Oncol Hematol 77:198–200
28. Kuderer N, Dale D, Crawford J et al (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158–67
29. 29 European Medicines Agency. Zarzio. Annex I. Summary of product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000917/WC500046525.pdf. Accessed 22 Nov 2014
30. Aapro MS (2012) What do prescribes think of biosimilars? Targ Oncol 7(Suppl 1):S51–S55
31. Weycker D, Hackett J, Edelsberg JS et al (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40:402–407
32. Gafter-Gvili A, Fraser A, Paul M et al (2012) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 201, CD004386
33. Aapro M, Cornes P, Abraham I (2011) Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract 18:171–179
34. Sun D, Andayani TM, Altyar A et al (2015) Potential cost savings from chemotherapyinduced febrile neutropenia prophylaxis with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European G5 countries: a simulation study. Clin Ther 37:842–857